Antibody durability at 1 year after Sputnik V vaccination

SANCHEZ, LAUTARO; OVIEDO ROUCO, SANTIAGO; PIFANO, MARINA; OJEDA, DIEGO S; PASCUALE, CARLA A; MAZZITELLI, BIANCA; DI DIEGO GARCIA, FACUNDO; GONZALEZ LOPEZ LEDESMA, MARÍA M; RODRIGUEZ, PAMELA E; MIGLIETTA, ESTEBAN A; CEBALLOS, ANA; ROSSI, ANDRÉS H; KREPLAK, NICOLAS; GEFFNER, JORGE; GAMARNIK, ANDREA V

LANCET INFECTIOUS DISEASES

ELSEVIER SCIENCE INC

Año: 2022 vol. 22 p. 589 - 590

1473-3099

Antibody waning against SARS-CoV-2 over time after vaccination, together with the emergence of new viral variants, pose great challenges for ending the pandemic. To our knowledge, no previous work has assessed the long-term prevalence of anti-SARS-CoV-2 antibodies in individuals vaccinated with Sputnik V (Gam-COVID-Vac).1 We assessed the persistence of anti-spike IgG antibodies and their neutralising capacity against the original SARS-CoV-2 lineage (B.1) and a local isolate of the BA.1 lineage of the omicron (B.1.1.529) variant in a longitudinal cohort during 1 year after Sputnik V vaccination in Argentina.